Recent advances in the bench-to-bedside translation of cancer nanomedicines

被引：1
作者：
Liu, Yang [1 ,2 ]
Zhang, Yinchao [1 ]
Li, Huikai [1 ,2 ]
Hu, Tony Y. [3 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Tianjins Clin Res Ctr Canc, Liver Canc Ctr, Natl Clin Res Ctr Canc,Dept Hepatobiliary Canc,Key, Tianjin 300060, Peoples R China
[2] Tianjin Canc Hosp Airport Hosp, Natl Clin Res Ctr Canc, Dept Hepatobiliary & Pancreat Oncol, Tianjin 300308, Peoples R China
[3] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA
来源：
ACTA PHARMACEUTICA SINICA B | 2025年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Cancer nanomedicines; Clinical translation; Clinical trial landscape; Anticancer; Tumor microenvironment; Combination therapies; Clinical nanotechnology; Drug delivery systems; TARGETED DRUG-DELIVERY; TUMOR MICROENVIRONMENT; PHOTOTHERMAL THERAPY; BREAST-CANCER; IN-VIVO; EXTRACELLULAR VESICLES; NANOPARTICLES; CHALLENGES; NANOMATERIALS; VACCINES;
D O I：
10.1016/j.apsb.2024.12.007
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Cancer remains a complex and challenging medical problem, driving extensive research efforts. Despite significant progress in understanding its genetic and molecular aspects, the quest for effective treatments continues. Nanomedicines have shown great potential for revolutionizing cancer treatment by offering targeted and controlled drug delivery, reducing side effects, and improving patient outcomes. Accordingly, nanomedicines have been the focus of extensive research and development for clinical translation. As of September 2024, a search on the ClinicalTrials.gov website using the term "nanoparticles" revealed numerous ongoing and planned clinical trials. Motivated by recent advances in the field, this review explores the current frontier of cancer nanomedicine. Nanomedicines have supported chemotherapy, phototherapy and sonodynamic therapy, nucleic acid therapy, and immunotherapy. However, translating nanomedicines into practice has been challenged by complex interactions between nanoparticles and biological systems, variable permeability and retention of nanoparticles in tumors, safety concerns, difficulty achieving targeted delivery, and issues with scaling up manufacturing. Perspectives on addressing these challenges are offered. Future opportunities for cancer nanomedicines, including modifying the tumor microenvironment, integrating artificial intelligence and big data, and targeting new medical areas, are also discussed. This review underscores the potential of cancer nanomedicines to revolutionize treatment from a clinical standpoint.
引用
收藏
页码：97 / 122
页数：26
相关论文
共 169 条
  • [21] Mumtaz, Khattak S., Rehman F.U., Muhammad P., Hanif S., Chapter 13 - bionanocomposites as a new platform for drug delivery systems, Novel platforms for drug delivery applications, pp. 289-315, (2023)
  • [22] Rehman F.U., Khattak S., Mumtaz S., Hanif S., Muhammad P., Chapter 10 - hybrid platforms for drug delivery applications, Novel platforms for drug delivery applications, pp. 217-255, (2023)
  • [23] Zhao S., Yu X., Qian Y., Chen W., Shen J., Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics, Theranostics, 10, (2020)
  • [24] Peng S., Xiao F., Chen M., Gao H., Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy, Adv Sci, 9, (2022)
  • [25] Kemp J.A., Kwon Y.J., Cancer nanotechnology: current status and perspectives, Nano Converg, 8, (2021)
  • [26] Zeng Y., Li S., Zhang S., Wang L., Yuan H., Hu F., Cell membrane coated-nanoparticles for cancer immunotherapy, Acta Pharm Sin B, 12, pp. 3233-3254, (2022)
  • [27] Mao L., Ma P., Luo X., Cheng H., Wang Z., Ye E., Et al., Stimuli-responsive polymeric nanovaccines toward next-generation immunotherapy, ACS Nano, 17, pp. 9826-9849, (2023)
  • [28] Shan X., Gong X., Li J., Wen J., Li Y., Zhang Z., Current approaches of nanomedicines in the market and various stage of clinical translation, Acta Pharm Sin B, 12, pp. 3028-3048, (2022)
  • [29] Bukhari S.N.A., Emerging nanotherapeutic approaches to overcome drug resistance in cancers with update on clinical trials, Pharmaceutics, 14, (2022)
  • [30] Soltani M., Moradi Kashkooli F., Souri M., Zare Harofte S., Harati T., Khadem A., Et al., Enhancing clinical translation of cancer using nanoinformatics, Cancers, 13, (2021)
12345678910